Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

por Reck, M., Barlesi, F., Crinò, L., Henschke, C. I., Isla, D., Stiebeler, S., Spigel, D. R.
Publicado 2012

A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung...

por Katakami, N., Felip, E., Spigel, D. R., Kim, J.-H., Olivo, M., Guo, M., Nokihara, H., Yang, J. C.-H., Iannotti, N., Satouchi, M., Barlesi, F.
Publicado en Ann Oncol (2017)

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

por Chiappori, A. A., Kolevska, T., Spigel, D. R., Hager, S., Rarick, M., Gadgeel, S., Blais, N., Von Pawel, J., Hart, L., Reck, M., Bassett, E., Burington, B., Schiller, J. H.
Publicado en Ann Oncol (2015)

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

por Gerber, D E, Horn, L, Boyer, M, Sanborn, R, Natale, R, Palmero, R, Bidoli, P, Bondarenko, I, Germonpre, P, Ghizdavescu, D, Kotsakis, A, Lena, H, Losonczy, G, Park, K, Su, W -C, Tang, M, Lai, J, Kallinteris, N L, Shan, J S, Reck, M, Spigel, D R
Publicado en Ann Oncol (2018)

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

por Bonomi, P D, Gandara, D, Hirsch, F R, Kerr, K M, Obasaju, C, Paz-Ares, L, Bellomo, C, Bradley, J D, Bunn Jr, P A, Culligan, M, Jett, J R, Kim, E S, Langer, C J, Natale, R B, Novello, S, Pérol, M, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Vansteenkiste, J F, Wakelee, H, Thatcher, N
Publicado en Ann Oncol (2018)